PTPRC and cancer: Incremental CTC count has been reported using a method based on the specific telomerase activation of cancer cells (OBP-401) [46], while folate receptor-positive CTCs [47], CK-19 mRNA-positive CTC [48], or DLL3+/CD45− CTCs [49], decrease during response.